Abstract | Our understanding of the mechanisms underlying HL A associations with inflammatory arthritis continues to evolve. Disease associations have been refined, and interactions of HL A genotype with other genes and environmental risk factors in determining disease risk have been identified. This Review provides basic information on the genetics and molecular function of HL A molecules, as well as general features of HL A associations with disease. Evidence is discussed regarding the various peptide-dependent and peptide-independent mechanisms by which HL A alleles might contribute to the pathogenesis of three types of inflammatory arthritis: rheumatoid arthritis, spondyloarthritis and systemic juvenile idiopathic arthritis. Also discussed are HL A allelic associations that shed light on the genetic heterogeneity of inflammatory arthritides and on the relationships between adult and paediatric forms of arthritis. Clinical implications range from improved diagnosis and outcome prediction to the possibility of using HL A associations in developing personalized strategies for the treatment and prevention of these diseases.
; they were recognized as important effectors of transplant rejection and immune responses to specific antigens, following pioneering studies on their murine homologues in the H2 gene region 3 (Box 1). Across species, this gene region is referred to as the major histocompatibility complex (MHC). The identification of HLA genes led to their intense investigation as inherited risk factors for conditions linked with autoimmunity, including rheumatic diseases. Among the earliest findings were the associations of HLA-B27 with ankylosing spondylitis (AS) 4, 5 and other spondyloarthritides (SpAs), including psoriatic arthritis, inflammatory bowel disease with SpA and reactive arthritis 6, 7 (TaBle 1) . Similarly, studies identified associations of HLA-DR4 and other HLA-DR molecules (which contain similar sequences at positions 70-74 of the β1 subunit, the so-called shared epitope (SE)) 8, 9 with rheumatoid arthritis (RA) ( TaBle 1) . These associations have been replicated extensively and refined using genome-wide association study (GWAS) data (reviewed elsewhere [10] [11] [12] ). Furthermore, HLA associations with many other rheumatic diseases have been identified, including, for example, with systemic sclerosis 13 , inflammatory myositis 14 and systemic lupus erythematosus (SLE) 15 . In general, different diseases are associated with different alleles of different HLA genes, although some alleles are associated with more than one disease.
The current paradigm for the pathogenesis of HLAassociated diseases holds that both genetic predisposition and environmental triggers contribute to disease development. HLA genes typically make the largest individual genetic contribution to inherited disease susceptibility, whether judged by the degree of confidence in the disease associations (extremely low P values) or by the magnitude of their effects on disease risk (high odds ratios) 16, 17 . However, these genes are thought to account for substantially less than half of the full genetic burden 18, 19 , the remainder being attributed to polygenic influences and, as yet, incompletely mapped [20] [21] [22] . Disease occurrence among genetically susceptible individuals (penetrance) is typically low, reflecting risk modification by hormones, environmental factors (for example, infection, the microbiota, lifestyle and diet) and stochastic effects on the formation of antigen receptor repertoires (such as in RA 23 ). Moreover, the importance of any one genetic contribution depends on the presence of other genetic factors (gene-gene interactions, also known as epistasis) or environmental factors (gene-environment interactions).
In this Review, we discuss HLA associations with diseases primarily characterized by inflammationdriven arthritis, such as RA, SpA and their paediatric counterparts. We also touch on other diseases in which inflammation-driven arthritis occurs, such as systemic sclerosis, SLE, dermatomyositis and systemic juvenile idiopathic arthritis (sJIA). We begin by describing the various HLA genes and functions of HLA molecules and summarize general features of HLA-disease
Epistasis
The ability of one gene to influence the effect of another gene on a phenotype (such as the risk of developing a rheumatological condition); also known as gene-gene interactions.
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associations. We present current hypotheses on the function of HLA risk alleles in disease aetiology, focusing on RA and SpA, in which mechanistic understanding is arguably the most advanced, and sJIA, in which an HLA association has recently been identified. Finally, we consider the clinical implications of HLA associations for diagnosis, prognosis, definition of disease subtypes, therapy and prevention.
HLA genes and molecules
The genes encoding HLA proteins are located in a region on chromosome 6, interspersed between other genes involved in immune recognition and regulation (Box 1; Fig. 1 ). HLA proteins have peptide-binding domains and are expressed at the cell surface, enabling peptides to be presented for inspection by T cells via clonally diverse αβ T cell receptors (TCRs) (Fig. 2) . Class I and class II HLA proteins are distinguished on the basis of their genomic location, expression, structure and function (Box 2; Figs 1,2). Class I HLA molecules primarily present peptides generated in the cytoplasm to cytolytic CD8 + T cells 24 (Box 2; Fig. 2a ). Class II HLA molecules bind peptides derived from endocytic processing, often after uptake from outside the cell, and present them to CD4 + T cells, which produce cytokines to regulate other immune cells (Box 2; Fig. 2b ). The recognition of HLAbound peptides by TCRs drives thymic selection and other tolerance mechanisms, as well as antigen-specific T cell responses to infection and, in autoimmunity, to self-proteins.
Pathogen-driven selection and diversification of HLA genes during evolution have resulted in multiple HLA class I and class II genes, and multiple alleles at any one gene (see Box 1) , such that most individuals are heterozygous at most HLA genes 1, 25 . Much of the amino acid variation in HLA class I and class II alleles affects the shape and charge distribution within the peptidebinding groove. These variations, in turn, control peptide side chain preferences at important positions in the peptide (anchor residues), yielding distinct repertoires of self-peptides and non-self-peptides that bind to each allele 26 . Databases of HLA class I-binding peptides and class II-binding peptides are available (for example, the Immune Epitope Database and Analysis Resource) 27 , as are algorithms that predict peptide-binding preferences for HLA alleles 28, 29 (epitope prediction software for MHC class I and class II molecules).
HLA associations with disease
Many investigations of HLA-disease associations have been case-control studies, which compare the frequency of HLA alleles between groups of healthy individuals and patients with a specific condition (for HLA typing methods, see Box 1) . In many of the initial studies, HLA association signals were broad and difficult to pinpoint because genetic recombination events in the HLA gene region rarely occur outside of a small number of recombination hot spots 1, 30 . Thus, clustered polymorphisms on the same chromosome are coinherited as haplotypes, spanning a number of adjacent HLA genes (linkage disequilibrium) 1, 30 . For example, particular HLA-DRB1 alleles are consistently accompanied by particular HLA-DQ alleles (which are closely linked, as shown in Fig. 1 ), and some extended haplotypes span much of the HLA region 31 . Distinguishing the diseaserelated alleles within these haplotypes has been a big challenge in the field.
The advent of high-density single-nucleotide polymorphism (SNP) arrays, which compare hundreds of thousands of SNPs between thousands of patients and controls, has helped to overcome this problem 12, 32, 33 . Systematic procedures can resolve broad association signals and pinpoint the associated polymorphic sites at one or a few HLA gene loci 22, 32, 34 . These fine-mapped associations reflect polymorphisms at particular amino acid positions of HLA proteins and often modulate peptide interactions, although other interactions can also be affected. Many of these redefined associations occur over diverse ethnic groups, updating an earlier impression that HLA associations tend to differ between ethnic groups 10, 35 . In some instances, the associated sites are polymorphisms in promoters that regulate the expression levels of HLA class II molecules (for example, promoters of HLA-DRB1, HLA-DQA1 and HLA-DQB1 in SLE or of HLA-DPB1 in systemic sclerosis) 36, 37 or are polymorphisms that regulate the expression of HLA region-encoded accessory proteins, which influence peptide loading (for example, HLA-DOA in RA and TAP2 in systemic sclerosis) [37] [38] [39] (Box 2;
HLA-disease associations can have gene dosage effects. Odds ratios are higher for homozygous than for heterozygous genotypes of risk alleles (for example, the associations of SE-containing DRB1 alleles with rheumatoid factor (RF)-positive RA 40 or polyarticular juvenile idiopathic arthritis (JIA) 41 and, in at least some studies, associations of HLA-B*27 with AS 42 ). In addition, in JIA, having an increased number of risk alleles has been correlated with a lower average age of disease onset 43 . HLA alleles associated with rheumatic diseases commonly confer increased risk of disease. Some HLA alleles, however, are less frequent in patients than in healthy individuals, implying that these alleles confer protection, either because they are less pathogenic than typical HLA alleles or because they mediate an anti-inflammatory
Key points
• The HlA gene complex is one of the best-studied regions of the human genome, and technical advances continue to deepen our understanding of its associations with inflammatory arthritis. ).
Mechanisms of HLA-disease associations Different rheumatic diseases are associated with different HLA genes, suggesting that there is no unifying mechanism underpinning these associations. Conversely, as some HLA gene associations are shared for different diseases, some mechanistic features might also overlap. This idea is exemplified by the SpAs, all of which are associated with HLA-B*27 (reviewed elsewhere 7 ). Indeed, the association of HLA-B*27 with disease in adults, adolescents and children with SpA suggests the existence of similar underlying mechanisms across the age spectrum 33 . Likewise, the expression of SE-containing HLA-DRB1 alleles in both adults with RF-positive RA and paediatric patients with RF-positive polyarticular JIA suggests overlapping mechanisms 45 . In this section, we summarize the current data and concepts concerning the mechanisms of HLA association with RA, SpA and sJIA.
RA and the HLA-DRB1 alleles RA is characterized by symmetrical, typically erosive polyarthritis affecting distal joints. Anti-citrullinated protein antibodies (ACPAs) and RF autoantibodies are common diagnostic features of RA, and their presence is associated with worse outcomes 46 . Twin studies indicate that this disease has a heritability of 53-68%, with little difference in heritability between ACPA-positive and ACPA-negative RA or between ethnic groups [47] [48] [49] . For ACPA-positive RA, the contribution of SE-containing HLA-DRB1 alleles explains ~20% of the genetic risk, but it accounts for only a small percentage of the genetic risk of ACPA-negative RA 48 . TaBle 1) 9 . Structural studies showed that the SE influenced the side chain preferences of a pocket (P4) in the peptidebinding groove of HLA-DR and included both TCR and peptide contact residues in the β chain region flanking the bound peptide 51 ( Fig. 3a ). An informative exception was an HLA-DR4 allele, HLA-DRB1*04:02, which was not associated with an increased risk of RA [52] [53] [54] . HLA-DRB1*04:02 encodes an HLA molecule containing a different sequence (DERAA) in place of the SE sequence (that is, residues 70-74), reversing the charge at the P4 pocket 9 . This finding provided evidence that HLA-DRB1, rather than another closely linked gene within the HLA-DRB1*04 haplotype, is the principal susceptibility locus 52 40 . In 2012, GWAS data identified a minimal set of SNPs that explained the association of HLA-DRB1 with RA 34 . This analysis confirmed the importance of residues K71 and A74 in the traditional SE of HLA-DRB1 in disease susceptibility and identified an even stronger contribution from residue 11 in the P4 pocket in the floor of the peptide-binding site (Fig. 3a, left) . These three residues explained all other association signals in HLA-DRB1, including residue 13, which is in linkage disequilibrium with residue 11 (ReF. 34 ). Independent RA associations with single amino acid polymorphisms in HLA-B and HLA-DPB1 were also identified 34 . Similar patterns were found in an Asian RA cohort 35 .
Whether the protective effect of some HLA-DRB1-related associations is because of the presence of specific HLA-DRB1 alleles, such as HLA-DRB1*13 (ReFs 44, 54 1, 219 . The HlA region contains a dense cluster of immune-related genes (Fig. 1) , of which the genes encoding classical transplantation antigens (that is, the peptide-binding HlA class I and class II glycoproteins) have the greatest allelic polymorphism. As a result, most individuals are heterozygous at most HlA class I and class II gene loci, and paternally inherited and maternally inherited allelic variants at these loci are co-dominantly expressed. Thousands of alleles at several classical HlA class I and class II genes have been sequenced, and any two alleles typically differ at multiple nucleotide positions.
There is a well-established nomenclature for HlA genes 220 (see HlA system nomenclature for detail). letters (A, B and C for class I and DP, DQ and DR for class II) designate each locus; for class II genes, A and B suffixes (such as DRA and DRB) are used to designate genes coding for the α and β chain polypeptides, respectively. Additional loci encoding alternative HlA-DR β chains, which are present in some haplotypes, are numbered (for example, DRB4). locus names are followed by an asterisk and several pairs of digits, separated by colons, which identify the following types of allelic variation, in order: the major variants correlating with HlA serotypes; all other coding variation; synonymous nucleotide substitutions in coding regions; and noncoding differences including promoter polymorphisms. HlA types were primarily characterized using serotyping with panels of alloantisera, which contain antibodies specific for alleles that differ from the serum donor. For clinical purposes, HlA typing is now performed by a combination of molecular and immunological techniques 222 . When microarrays are employed for genome-wide analysis of single-nucleotide polymorphisms (SNPs), HlA gene region SNPs together with data in reference panels can be used to infer a reasonably accurate HlA genotype by a process called imputation 223 (for example, using the HlA-check tool and the genome-wide SNP database). Complete nucleotide sequencing is the gold standard for HlA genotyping 224 .
www.nature.com/nrrheum sequence DERAA in place of the SE, or the presence of particular amino acids at certain positions (such as isoleucine at position 67 or aspartic acid at position 70 (ReFs 55, 56 ) ) is yet to be fully resolved but is an active area of research.
Interestingly, mothers who have an SE-containing HLA-DRB1 allele might pass an increased risk of developing RA on to their children (irrespective of whether the child inherits the SE-containing HLA-DRB1 allele) because of the influence of non-inherited maternal alleles (NIMAs) (reviewed elsewhere 57, 58 ). This process is thought to relate to maternal cells entering the fetal circulation and shaping immune system development, but the effect of NIMAs on RA risk has not been confirmed in all studies, and the mechanistic implications remain unclear. . This allele has the sequence RRRAE in place of the SE. 102 . Results in a Taiwanese cohort are similar 101 .
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Gene-environment interactions involving the SE.
Epidemiological studies of ACPA-positive RA have provided striking evidence for a gene-environment interaction: two environmental factors, smoking and gingivitis, increase the risk of RA, but only in carriers of SE-containing HLA-DRB1 alleles [59] [60] [61] [62] [63] . Both smoking and gingivitis induce protein citrullination, a posttranslational modification of positively charged arginine residues to citrulline, which is catalysed by peptidylarginine deiminases (PADs) 64 ( Fig. 3b) . Smoking-induced inflammation upregulates host PAD enzymes in the lungs 59 . Porphyromonas gingivalis, a bacterium associated with gingivitis, has its own PAD enzyme, whereas another gingivitis-associated pathogen, Aggregatibacter actinomycetemcomitans, produces a toxin that induces hypercitrullination of proteins in neutrophils and promotes their extracellular release 62 . This evidence suggests a model in which the SE confers risk of autoreactivity directed against citrullinated self-proteins, which are generated at sites of neutrophilic inflammation. The self-reactive lymphocytes and autoantibodies might then attack the joint.
Neoantigen hypothesis. An attractive hypothesis is that, in RA, citrullination can make some self-antigens appear as non-self to the immune system, which can lead to the loss of self-tolerance (known as the neoantigen hypothesis). This hypothesis might explain the association of ACPA-positive RA with the SE of HLA-DRB1, as citrullination differently affects the binding of some peptides to SE-containing HLA-DR proteins (Fig. 3a) and to HLA-DR proteins without the SE (Supplementary Fig. 1 ). Some . In the telomeric class I region (top), the HL A-A, HL A-C and HL A-B genes encode classical class I heavy chains (also known as class Ia genes), which assemble with β 2 -microglobulin (encoded on chromosome 15). Classical class I and II genes display extraordinary allelic variation, except for HL A-DRA 1 . Interspersed among the class II loci are genes that regulate antigen presentation, such as TAP1 and TAP2 and PSMB8 and PSMB9, which function in the class I pathway , as well as genes for HL A-DM and HL A-DO, which function in the class II pathway 86, 225, 234 (explained in Box 2). The HL A class I region contains genes encoding non-classical class Ib heavy chains, which are not involved in peptide presentation to CD8 + T cell receptor (TCR) αβ + T cells
The class III region encodes non-polymorphic immune molecules that are not directly involved in antigen presentation (such as complement components and TNF).
Neoantigen an antigenic peptide that arises from the posttranslational modification of a self-protein, thus making it appear foreign or new; the generation of such peptides is a proposed mechanism for breaking self-tolerance.
www.nature.com/nrrheum studies of foreign peptides provide evidence that the P4 pocket of HLA-DR0401 accommodates neutral, polar or negative side chains but is far less accommodating to positively charged arginine residues [65] [66] [67] . These findings suggest that some HLA-DR proteins are unable to bind and present self-peptides that have arginine residues at position P4 (the residue that binds the P4 pocket) under non-inflammatory conditions (when a PAD is unavailable) and thus fail to induce tolerance. Citrullination of the arginyl side chains of these peptides, which neutralizes their positive charges, can occur in inflammatory states when a PAD is released by neutrophils 59, 62 . Hence, the resulting P4-citrullinated self-peptides might acquire the ability to bind HLA-DR0401 molecules 68, 69 , enabling their presentation to, and stimulation of, effector and memory CD4 + T helper cells, which are expanded in the circulation of patients with RA 69 (Fig. 3a) . This process probably also results in the activation of B cells that recognize citrullinated self-antigens and subsequent ACPA production. Crystallographic studies and binding assays evaluating the interaction of HLA-DR0401 protein with several P4-citrullinated self-peptides confirm that citrullination can promote this interaction 69, 70 . Studies of interactions between other SE-containing HLA-DR variants and peptides have shown, however, that the amount of binding gained from P4 citrullination is variable, and in several cases, no gain is apparent, suggesting that the magnitude of the effect is context- . a | MHC class I molecules acquire peptides from proteasome-mediated degradation of cytosolic proteins. These peptides are imported into the endoplasmic reticulum (ER) by the transporter associated with antigen presentation (TAP1 and TAP2), trimmed by ER aminopeptidases (ERAPs) and loaded onto nascent class I heavy chain-β 2 -microglobulin (β 2 m) complexes associated with TAP, tapasin and other components (not shown). Tapasin ensures selection of a stable class I-bound peptide repertoire by promoting peptide exchange. In the ER and Golgi apparatus, class I molecules might further associate with the tapasin-related protein TAPBPR with consequences that are as yet unclear 235 . After transport to the cell surface, the MHC class I molecules present bound peptides to CD8 + T cells. b | Nascent MHC class II molecules bind to the invariant chain (Ii) polypeptide in the ER . After transport to endosomes, Ii is trimmed, leaving class II-associated invariant chain peptides (CLIPs) in the peptidebinding groove. HL A-DM promotes the exchange of CLIPs for peptides generated in the endocytic pathway , but HL A-DO can also bind to and inhibit HL A-DM. After transport to the cell surface, MHC class II molecules present bound peptides to CD4 + T cells. TCR , T cell receptor.
NATURE REvIEWS | RHeuMATOLOgy dependent 70, 71 . Citrullination at other anchor or nonanchor residues usually has no effect on (or weakens) binding 70, 72 . Importantly, to support a neoantigen hypothesis, it is not necessary to postulate that all P4 citrullination events result in improved binding to SE-containing HLA-DR alleles -the loss of tolerance to a small number of neoantigens might be enough to explain an increased disease risk.
Similar considerations might answer the reverse question of why other HLA-DRB1 alleles, such as HLA-DR0402, have no association with ACPApositive RA (Supplementary Fig. 1 ). HLA-DR0402 can bind P4-citrullinated peptides, but unlike HLA-DR0401, this variant can also bind the unmodified (P4-arginine-containing) peptides, suggesting that the parent (uncitrullinated) peptides can induce tolerance 69 ( Supplementary Fig. 1a ). The binding (or lack of binding) of self-peptides to other HLA-DR alleles is presumably unaffected by citrullination of arginine residues ( Supplementary Fig. 1b) , as apart from their different charges, arginine and citrulline are very similar in structure. Citrullination might also affect other aspects of antigen presentation in RA (for example, by modifying the proteolytic processing of self-proteins), but there is no known reason for these other aspects to select for SE-containing HLA-DRB1 alleles 2, 69 . Another mechanism has been proposed 73 to explain the protective effects of HLA-DRB1*13 in ACPA-positive RA, although confirmation is still needed. HLA-DR13 (encoded by HLA-DRB1*13) contains the DERAA sequence and is proposed to be broken down into peptides with a DERAA core that bind to HLA-DQ 73 . These peptides induce T cell tolerance against homologous microbial peptides and citrullinated vinculin peptides, to which ACPA-positive patients with RA would otherwise mount pathogenic T cell responses.
The discovery of anti-carbamylated protein (antiCarP) autoantibodies in a subset of patients with RA has raised new questions about the mechanisms by which post-translational modifications break self-tolerance. Carbamylation is a post-translational modification of lysine to homocitrulline mediated by cyanate; during oxidative stress, neutrophil myeloperoxidase can mediate the transformation of thiocyanate into cyanate, hence promoting carbamylation (Fig. 3b) . Anti-CarP autoantibodies and ACPAs are not usually co-expressed in the same patients and do not seem to cross-react with each other 74 . Furthermore, anti-CarP antibodies are not associated with the SE or with smoking 75 . The effect of lysine carbamylation on the interactions between selfpeptides and SE-positive HLA-DR alleles has not been characterized, but the presence of lysine at P4 does not seem to strongly affect the binding of foreign peptides to SE-containing HLA proteins 65 . Hence, the SE might not influence the generation of responses against carbamylated self antigens, explaining the lack of an association between the SE and anti-CarP autoantibodies. However, the mechanism by which carbamylation breaks self-tolerance remains unresolved.
The neoantigen model is attractive because it accounts for the selective presence of ACPAs (but not anti-CarP autoantibodies) in patients with RA who carry SE-containing HLA-DRB1 alleles; these alleles discriminate between certain unmodified peptides (which contain arginine at P4) and post-translationally modified peptides (which contain citrulline at P4). Notably, analogous mechanisms have been identified in coeliac disease and in type 1 diabetes, wherein tissue transglutaminase creates neoantigens that bind to HLA-DQ risk alleles 76, 77 .
Calreticulin signalling hypothesis. Another mechanistic hypothesis to explain the association of SE-containing HLA-DRB1 alleles with RA proposes that the SE region of the HLA-DR β chain can bind calreticulin and promote cell signalling ( Supplementary Fig. 2a ).
Calreticulin was discovered as a calcium-binding protein that chaperones nascent glycoproteins in the endoplasmic reticulum (ER); however, this protein can also translocate to the plasma membrane in damaged cells where it promotes phagocytosis of the cell 78 . SE-containing peptides or intact SE-containing HLA-DR molecules
Box 2 | Function of MHC molecules
The major immune function of MHC molecules is to enable T cells to detect host cells that have been exposed to infectious pathogens 225 . In such host cells, foreign proteins are degraded (processed), and the resultant peptides bind to mHC proteins, which are then displayed (presented) on the plasma membrane, where they can activate T cells (Fig. 2) . The T cell receptor (TCR) interacts with parts of the peptide and parts of the mHC molecule (known as dual recognition) [226] [227] [228] . MHC class I mHC class I molecules (HlA-A, HlA-B and HlA-C in humans) acquire peptides derived from cytosolic protein degradation by the proteasome, transported by TAP transporters and trimmed by endoplasmic reticulum (ER) aminopeptidases (ERAPs) (Fig. 2a) . The TAP1 and TAP2 subunits of the peptide transporter, and PSmB8 and PSmB9, two cytokine-inducible proteasome subunits, are encoded in the HlA class II region (Fig. 1) . In cells infected with cytosolic pathogens, pathogen-derived peptides enter the class I pathway and are presented to CD8 + T cells, which then kill the infected cells. In addition, mHC class I-self-peptide complexes on healthy host cells engage inhibitory receptors on natural killer (NK) cells, delivering signals that protect the healthy cells from NK cell-mediated attack 229 . Diminished mHC class I expression on stressed or infected cells removes this inhibition, making them more susceptible to NK cellmediated cell death.
MHC class II mHC class II molecules (HlA-DR, HlA-DQ and HlA-DP in humans) are constitutively expressed on professional antigen-presenting cells (APCs; such as monocytes and/or macrophages, dendritic cells and B lymphocytes), which take up pathogens or their products. mHC class II molecules acquire peptides derived from endocytic processing of these exogenous antigens (Fig. 2b) and present them to CD4 + T cells, which then activate or regulate effector responses through cell surface interactions or cytokine release 24 . Endogenous peptides present in endosomes (for example, derived from autophagy of cytosolic proteins) can also become bound to mHC class II molecules 230 . mHC class II αβ dimers are synthesized in the ER, associate with invariant chain (Ii) and are delivered to endosomes, where Ii is degraded by proteases. The subsequent release of residual class II-associated invariant chain peptides (ClIPs) from the peptide-binding groove by HlA-Dm creates mHC class II molecules competent for peptide loading (Fig. 2b) . HlA-Dm and its inhibitor, HlA-Do, are also encoded in the mHC class II region (Fig. 1) .
Tolerance induction
Importantly, mHC proteins are occupied by a diverse cargo of self-peptides (≥10 4 distinct species), arising from the physiological turnover of host proteins 26, 225, 231 .
Presentation of these peptides to T cells by APCs in the thymus, including thymic epithelial cells, and at extra-thymic sites in the absence of inflammation induces T cell tolerance 232
, whether by T cell elimination (clonal deletion), anergy or differentiation into regulatory T cells.
www.nature.com/nrrheum bind calreticulin 79 , which stimulates pro-inflammatory changes, such as nitric oxide production, in antigenpresenting cells (APCs) in a CD91-dependent fashion 80 . The same interaction has been proposed to explain how, in CD8 −
CD11c
+ dendritic cells, SE-containing peptides trigger the production of IL-6 and IL-23, which activate T helper 17 (T H 17) cells, whereas in CD8 + CD11c
+ dendritic cells, the same stimulus inhibits the production of indoleamine 2,3-dioxygenase (IDO), an enzyme important in regulatory T cell activation 81 . A cyclized SE-containing peptide can bind calreticulin, enhance osteoclast differentiation and activation in vitro and exacerbate bone erosion in murine arthritis 82 ; these processes could contribute to erosive disease in patients with RA who have SE-containing DRB1 alleles 83 . Intriguingly, citrullination of calreticulin increases its affinity for the SE, providing a link between the SE and environmental factors known to increase the risk of erosive RA 84 .
However, these SE-linked innate immune effects do not explain the presence of anti-citrullinated protein responses in RA.
Low CLIPc affinity hypothesis. Another mechanistic hypothesis derives from the observation that SEcontaining HLA-DR molecules have a low affinity for class II-associated invariant chain peptides (CLIPs), the nested set of invariant chain (Ii) fragments that occupy the peptide-binding groove before the exchange for endosomal peptides during HLA class II-peptide complex assembly 85 ( Fig. 2b) . For most HLA class II alleles, efficient peptide exchange requires the accessory molecule HLA-DM (Fig. 2b) , but alleles with a lower affinity for CLIPs, such as HLA-DR0401, can release CLIPs spontaneously and might load peptides without the participation of HLA-DM 86 ( Supplementary Fig. 2b ). HLA-DM selects for a stably bound peptide repertoire, and hence, , and the other residues in the 70-74 β chain region (the shared epitope (SE)) are shown in gold. Depicted on the right is the neoantigen model. SE-containing HL A-DR variants present modified peptides with electrically neutral citrulline residues at P4, but they cannot present the unmodified parent peptides containing positively charged arginine at P4, which might result in non-tolerant CD4 + T cell effector responses to the citrullinated peptide. In patients with an SE-containing HL A-DR allele, tolerogenic vaccination with citrullinated peptides might be a viable strategy for restoring normal immune regulation (red arrow). b | Peptidylarginine deiminases (PADs) mediate calcium-dependent citrullination of arginine residues on polypeptide chains (left). In the presence of cyanate (generated by oxidation of thiocyanate by neutrophil myeloperoxidase (MPO) at sites of inflammation 236 ), lysine residues are carbamylated to homocitrulline (right), which is identical to citrulline except for an extra methylene group 74 . Inhibition of neutrophil enzymes (red arrow) might disrupt the presentation of neoantigens that perpetuate autoimmunity.
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HLA-DR protein variants with low CLIP affinity might acquire less stably bound peptides; indeed, such HLA-DR variants have been shown to undergo increased peptide exchange at the cell surface 86 . This process can promote loss of self-tolerance; for example, at sites of inflammation, extracellular proteases generate peptides (neoepitopes) that can be presented by HLA molecules owing to peptide exchange at the surface of APCs. The spontaneous release of CLIPs and subsequent loading of weakly bound peptides are also associated with a faster turnover of HLA class II molecules, leading to lower surface expression of this molecule, which could impair central and peripheral tolerance mechanisms 87 . Whether low CLIP affinity is relevant to the contribution of the SE of HLA-DRB1 to RA susceptibility remains unclear, but some evidence implicates this mechanism in other HLA associations. The presence of glycine at position 84 of HLA-DPB1 impairs the folding of the CLIP region of Ii into its peptide-binding groove 88 . This impairment enables endosomal peptide loading of HLA-DP without HLA-DM editing 89 ( Supplementary  Fig. 2b ), as well as premature loading of TAP-transported peptides in the ER 90 . Intriguingly, this polymorphism has been associated with susceptibility to ACPA-positive RA (and other diseases) in Japanese individuals 39 . Moreover, in the nonobese diabetic mouse model of type 1 diabetes, mutagenesis of a CLIP to strengthen its binding to a low-CLIP-affinity class II allele protected against disease 91 .
Influence of the SE on the microbiota. Members of the intestinal microbiota are known to affect immune regulation and autoimmunity, and HLA genes might, in turn, influence the composition of the intestinal microbiota. For example, compared with healthy individuals, the abundance of Prevotella copri was increased in the intestines of patients with new-onset RA but not in patients with established RA 92 . However, even though the abundance of P. copri was influenced by HLA genes, this bacterium was most abundant in patients without SEcontaining DRB1 alleles 92 , arguing against a mechanism whereby SE-containing risk alleles promote the expansion of arthritogenic microbiota members. In HLA-DR4-transgenic mice, the expression of SE-containing alleles is associated with increased intestinal permeability, complex alterations in microbial composition and the intestinal expression of type 17 cytokines 93 , but the relevance of these findings to RA remains unclear.
Spondyloarthritis and HLA-B27
The SpAs share associations of varying strength (greatest for AS) with HLA-B*27:05 and other HLA-B*27 subtypes, of which over 100 have been identified, although only the more prevalent subtypes have been examined for disease associations 94 ( TaBle 1) . SpA characteristically affects the spine and sacroiliac joints, although other clinical features include extra-articular enthesitis, peripheral arthritis (particularly in the lower limbs) and osteitis 95 . The expression of HLA-B*27:05 in rats and mice causes joint pathology with some features of SpA 96 . Disease manifestations in HLA-B*27 transgenic rats include destructive arthritis, enthesitis, spondylitis and ankylosis, which resembles human disease more closely than the disease in HLA-B*27 transgenic mice 96 . Data from an early twin study indicated that, although AS risk is mostly controlled by genetic rather than environmental variation, the HLA-B*27 genotype contributes less than half of the heritable component 97 . More recently, researchers reported that HLA-B*27 contributes 20.1% of the heritability of AS and identified other genes that could explain 4.3% of the heritability, although the majority of the genetic heritability remained unexplained 22 . In 2010, additional AS-associated genes were identified in a GWAS 17 , including the gene that encodes endoplasmic reticulum aminopeptidase 1 (ERAP1), which mediates amino-terminal trimming of class I-bound peptides in the ER during HLA class I peptide loading 17 .
Variants of ERAP1 associated with a reduced enzymatic activity against certain peptide substrates have been reported to be protective against AS [98] [99] [100] . In SpA, inflammation of the sacroiliac and intervertebral joints is associated with both erosive bone changes and new bone formation at the entheses. HLA-B27 does not directly affect bone formation in transgenic mice or osteoblast differentiation by mouse or human bone precursor cells in vitro 81 ; rather, epigenetic and gene expression analyses suggest that new bone formation occurs in SpA owing to HLA-B27-driven inflammation 104, 105 . The mechanistic hypotheses proposed to account for these findings are depicted in Fig. 4a and explained in the remainder of this section.
Arthritogenic peptide hypothesis.
A possible source of HLA-B27-driven inflammation in SpA is the presentation of pathogen-derived, arthritogenic peptides (that is, exogenous peptides that are sufficiently similar to self-antigens to incite autoimmunity) to CD8 + T cells and the resulting selection of high-affinity autoreactive T cells (similar to the high-affinity T cell selection that occurs during repeated antigen presentation in chronic infections 106 ). T cells that recognize HLA-B27-bound candidate arthritogenic peptides from intracellular bacteria have been identified in patients with reactive arthritis 107 . NATURE REvIEWS | RHeuMATOLOgy disease could result from differences in features of peptides bound to disease-associated versus non-associated HLA-B27 alleles [108] [109] [110] [111] , the presentation of which by the former could lead to the selection of autoreactive T cells. However, no qualitative differences between peptides that can bind these allelic groups have been identified 112 . Nonetheless, consistent with an antigen-driven process, oligoclonal T cell expansions are present in the blood and at sites of inflammation in patients with SpA [113] [114] [115] . Interestingly, joint-infiltrating CD8 + T cells that, unusually, produce IL-17 have been detected in patients with PsA 116 . Indeed, arthritis risk in patients with psoriasis has been linked to HLA-B*27, specifically glutamic acid at position 45 (ReF.
117
) and asparagine at position 97 (ReF.
118
), both of which are located in the peptide-binding groove and are likely to influence peptide presentation 119 (Fig. 4b) .
However, in transgenic rats with high copy numbers of the HLA-B*27 transgene, CD8 + T cells are not required for the development of arthritis and intestinal disease 120 . This finding, together with the low frequencies of self-reactive or cross-reactive CD8 + T cells in patients with other SpAs, such as AS, and the apparent function of T H 17 cell-derived cytokines in SpA 103 , suggests that HLA-B27-restricted CD8 + T cell involvement cannot fully account for SpA. However, failure to control the activity of high-avidity autoreactive CD8 + T cells could contribute to pathogenesis in some types of SpA, such as reactive arthritis and PsA.
Cell surface open conformations of HLA-B27. Another mechanistic hypothesis to explain the association of HLA-B*27 alleles with SpAs is based on the fact that a free cysteine (Cys67; Fig. 4b ) (and perhaps other cysteines) 121 in HLA-B27 heavy chains promotes the formation of peptide-free, open conformations of HLA-B27 heavy chains (including dimers and possibly other forms), which do not complex with β 2 -microglobulin. Such open conformations are expressed at the cell surface and participate in pathogenic immune signalling [122] [123] [124] ( Fig. 4a) . Cell surface HLA-B27 open conformations are generated from unstable peptide-HLA-B27 complexes during HLA class I recycling 122 . Cys67-dependent HLA-B27 homodimer formation has been detected on the cell surface of HLA-B27-transfected B cell lines, immune cells from patients with SpA and monocytes from HLA-B*27 transgenic rats 122, 123, 125, 126 . For example, the expression of HLA-B27 homodimers is increased on cells in the inflamed intestine and joints of patients with SpA 125, 127, 128 . Additionally, in an HLA-B*27 transgenic rat model of arthritis, the expression of open conformations of HLA-B27 on immune cells increases with disease progression 126 . In addition to HLA-B27 homodimers, HLA-B27 could also dimerize or oligomerize with other cell surface molecules, such as HLA-F, which binds to disassembling HLA class I molecules 122, 129 . The enzymes ERAP1 and ERAP2 trim peptides and control the supply of appropriately sized peptides for class I binding, thus controlling the rate of formation of cell surface peptide-HLA-B27 complexes (Fig. 2a) and the resulting HLA-B27 open conformations (Fig. 4a) . The evidence linking specific ERAP1 alleles with differences in the levels of HLA-B27 heavy chain open conformations is controversial. In one report, SpA-associated ERAP1 variants were associated with increased production of HLA-B27 open conformations 130 . Protective ERAP1 variants were associated with reduced cell surface expression of class I heavy chains on cell lines and cells from patients with SpA 130 . In this study, gene silencing or pharmacological inhibition of ERAP1 reduced the expression of HLA-B27 open conformations, reduced their binding to killer cell immunoglobulin-like immune receptors (KIRs) and reduced T cell-mediated production of IL-17 in both in vitro and ex vivo experiments 130 . By contrast, in other studies, ERAP1 gene silencing and the expression of protective ERAP1 variants increased the cell surface expression of HLA-B27 open conformations and intracellular formation of HLA-B27 heavy chains 131, 132 . These observations highlight the difficulties with extrapolating data from cell lines overexpressing HLA-B27 to disease. As ERAP1 affects the supply of peptides to HLA-B27, differences in the expression of ERAP1 and HLA-B*27 genes in patients and experimental systems could contribute to these contradictory observations.
Unlike peptide-HLA-B27 complexes, which interact with the TCR, HLA-B27 open conformations bind strongly to the inhibitory killer cell receptor KIR3DL2 and to the leukocyte immunoglobulin-like receptor (LILR) family members LILRB2 (also known as LIR2) and LILRB5 (ReFs 133, 134 ). HLA-B2705 proteins form more open conformations that bind to KIRs and LILRs than the non-disease-associated HLA protein HLA-B2709 (ReF. 135 ). KIR3DL2 is expressed on natural killer (NK) cells, γδ T cells and activated CD4
+ and CD8 + αβ T cells 136, 137 . KIR3DL2 also binds to other class I heavy chains, including HLA-F, which has also been linked to SpA 138, 139 . However, KIR3DL2 binds more strongly to open conformations of HLA-B27 than to other HLA class I heavy chains 140 . LILRB2 and LILRB5 receptors that can bind HLA-B27 open conformations are expressed on monocytes and osteoclasts [141] [142] [143] [144] . . These cells also express markers of activated T cells and other markers that suggest migration from the intestine, and they show evidence of oligoclonal expansion 145, 147 . Inhibiting the binding of KIR3DL2 to HLA-B27 open conformations on transfected cells and on cells that naturally express HLA-B27 both inhibits the survival of activated T cells from patients with SpA and healthy individuals in vitro and limits IL-17 production by T cells from patients with SpA ex vivo 145, 148 . HLA-B27 misfolding, the unfolded protein response and autophagy. HLA-B27-mediated activation of the unfolded protein response (UPR), a cellular response to ER stress, and its putative contribution to arthritis have been extensively reviewed elsewhere 151 . The free Cys67 and other molecular properties of HLA-B27 heavy chains promote HLA-B27 misfolding in the ER 151 . Inefficient intracellular disposal of misfolded molecules causes ER stress and promotes the production of inflammatory mediators through the induction of the UPR 151, 152 . Misfolded proteins in the ER are disposed of by ER-associated degradation (ERAD). The slow assembly of peptide-HLA-B27 complexes predisposes the cell to increased levels of ERAD, the induction of a UPR and autophagy, especially when HLA-B27 production is upregulated during inflammation 151 . Disease-associated HLA-B27 subtypes oligomerize, accumulate in the ER more readily and are more susceptible to ERAD than non-disease-associated HLA-B27 subtypes [153] [154] [155] . Increased sequestration of unfolded HLA-B27 by the ER chaperone BiP (an immunoglobulin binding protein) increases the expression of UPR-related genes and pro-inflammatory immune genes, such as that encoding IL-23 (ReF. 156 ). The UPR also promotes the production of IL-1α and IFNβ, which increase and inhibit T H 17 cell differentiation, respectively. Autophagy, induced as a consequence of a UPR, also promotes IL-23 production.
In HLA-B*27 transgenic rats, which express very high levels of HLA-B27, misfolded HLA-B27 drives the UPR in macrophages 157 and is associated with increased osteoclast formation 158 . However, there are conflicting reports concerning whether the UPR is upregulated in mononuclear cells and macrophages from the synovial tissue of patients with SpA 154, 159, 160 . Although one study showed upregulation of BiP in mononuclear cells from peripheral joints of patients with AS 134 , a later study showed that activated macrophages from patients with SpA produced more IL-23 than those from healthy individuals but without any notable upregulation of the UPR 161 . Other studies showed that, although autophagy was increased without an ongoing UPR in the intestinal tissue of patients with SpA, autophagy was not upregulated in their peripheral blood or joints 162, 163 . Furthermore, disease-associated polymorphisms in ERAP1 are not correlated with ER stress in patients with AS 164 . Overall, further work is needed to distinguish the direct effects of HLA-B27 on ER stress and the UPR from effects occurring downstream of inflammation.
HLA-B27 and the microbiome
The biological effects of HLA-B27 could influence SpA pathogenesis by shaping the microbiome. HLA-B27 promotes the survival of Gram-negative intracellular bacteria in transfected monocyte cell lines and in HeLa epithelioid cell lines expressing HLA-B27 (ReFs 165, 166 ).
In vivo, any possible direct effects of HLA-B27 on the survival of microorganisms that promote arthritis are difficult to distinguish from the effects of an ineffective immune response. In HLA-B*27 transgenic rats, antibiotic administration inhibits osteoclast formation and attenuates arthritis 167 . HLA-B*27 transgenic rats have an increased susceptibility to Gram-negative intracellular bacterial infections, which could trigger the development of SpA-like manifestations 168, 169 . Perturbations in the intestinal microbiome in rodent SpA-like disease and human SpA could be because of imbalances in type 1 and type 17 cytokine production 170, 171 . In 2018, a study of HLA-B*27 transgenic rats emphasized the relationship between the host genetic background and associated changes in multiple microorganisms in establishing an inflammatory environment that promotes arthritis 172 . This area of research is currently under intense investigation in human studies.
Systemic JIA and HLA-DR
In many inflammatory arthritides, the mechanisms underpinning HLA-disease associations are less well understood than in RA and SpA, especially where structural studies have not provided mechanistic clues, as exemplified by sJIA. GWAS data from patients of European ancestry identified an sJIA association with HLA-DRB1*11:04 and HLA-DRB1*11:01 (ReF. 173 ). The researchers pinpointed a residue in the HLA-DR β chain, glutamic acid at position 68, that conferred increased risk of sJIA; this residue does not interact directly with bound peptide. sJIA has many features of innate immune dysfunction, including systemic inflammation responsive to IL-1 and IL-6 inhibition 174 and the absence of RF and ACPAs (as well as the absence of antinuclear antibodies in most patients) 175 . However, some evidence supports a contribution from CD4 + T cells to established sJIA [176] [177] [178] [179] , and a subset of patients with sJIA develop chronic erosive arthritis without continued systemic features 180 . Thus, one model is that the initial phase of sJIA is dominated by innate immune activation and a subsequent phase is T cell dominant 181 . In this model, IL-1-driven development of T H 17 cells is important for progression to the second (arthritic) phase 182 . In line with this model, the HLA-DRB1*11 association could reflect HLA-DR-restricted T cell responses in this second phase 183 . Alternatively, as cell surface HLA-DR binds superantigens, which then engage and activate T cells that express particular TCRs 184 , an HLA-DR-superantigen interaction could be preferentially promoted by the HLA-DRB111 molecule 185 . Another possibility is that HLA-DR molecules could regulate innate immune responses in sJIA. For example, intracellular HLA-DR has been reported to influence Toll-like receptor signal strength in monocytes and dendritic cells 186 . Increased understanding of sJIA immunobiology is required to refine the mechanistic hypotheses on the association of HLA-DRB1*11 with this disease.
Clinical implications
Diagnosis and prognosis
For diagnosis, even the strongest HLA associations are generally insufficient alone because most people with risk alleles never develop the associated disease. However, strong HLA-disease associations can sometimes contribute to a diagnosis. For example, identifying the presence of disease-associated HLA-B*27 alleles, and thus a risk of SpA, can aid the diagnostic evaluation of back pain 187 . Another potential clinical application of HLA typing is early identification of individuals at high risk of arthritis among patients with psoriasis 188, 189 . One analysis identified glutamic acid at position 45 (which is in the peptide-binding groove of HLA-B*07, HLA-B*08, HLA-B*27, HLA-B*38 and HLA-B*39; Fig. 4b) as the critical risk factor associated with PsA in patients with psoriasis 117 . A second analysis, in which age of psoriasis onset was considered as a covariate, found that the primary risk of PsA in patients with psoriasis derives from asparagine (as found in HLA-B27) or serine (in HLA-B07 and HLA-B08) residues at amino acid position 97 of HLA-B 118 (Fig. 4b) . The discrepancy between the two studies might reflect differences in the clinical subtypes between PsA cohorts in the two studies, as there is evidence that HLA-B allelic associations might differ with PsA clinical phenotype 190 . Although mapping associations to amino acid residues is shedding light on PsA pathogenesis, in practice, screening of patients with psoriasis for arthritis risk, if proven useful, could involve employing HLA-B*27 genotyping in the near future 118 . The scope for using HLA genetic data in diagnosis and prognosis might increase as patient genomic data become more widely available. Importantly, HLA allele associations are also being used as part of quantitative polygenic risk scores, which are scores based on weighted contributions of alleles at multiple gene loci. By including variation in multiple genes (HLA and non-HLA related genes; for example, >100 loci for RA 191 ) and incorporating the effects of gene-gene interactions 192, 193 , polygenic risk scores can improve the prediction of inherited susceptibility for complex genetic traits, such as rheumatic diseases. Their clinical use is generally not imminent but holds promise for the future 194 .
Disease subtypes
Phenotypic subtypes of patients with the same clinical diagnosis can have distinct HLA associations, often with distinct autoantibody profiles. As discussed above, the most severe, erosive form of RA is associated both with HLA-DRB1 alleles that contain the SE 35, 60 and with seropositivity for RF, ACPAs or anti-cyclic citrullinated peptide (anti-CCP) autoantibodies, although whether ACPAs are merely markers or active drivers of disease severity is unclear 195 . Among patients with RA, carriers of SE-containing HLA-DRB1 alleles are also more responsive to DMARDs and some biologic therapeutics than non-carriers 195, 196 . Interestingly, the protective effect of the HLA-DRB1*13 allele seems to be confined to ACPA-positive RA 197 . HLA-DR alleles are not always the primary risk factors for particular subgroup associations; for example, HLA-DQB1*03:01 is associated with bronchiectatic airway disease and emphysema in RA, whereas HLA-DQB1*03:02 confers resistance to these conditions 198, 199 . Additional examples of autoantibody-defined patient subsets with different associated HLA alleles include dermatomyositis and systemic sclerosis. In dermatomyositis, carriage of antibodies against Mi-2 (a nuclear antigen) is associated with HLA-DRB1*07:01, whereas carriage of antibodies against transcription intermediary factor 1 (TIF1-γ) is associated with HLA-DQB1*02 (ReF.
200
). In systemic sclerosis, the two main serological patient subsets, defined by carriage of anti-centromere antibodies or anti-topoisomerase (anti-Topo I) antibodies, are also distinguished by genetic differences at HLA class II loci 37, 201 : ), those for RF-positive polyarticular JIA are SE-containing HLA-DRB1 alleles 205 , and those for systemic JIA are HLA-DRB1*11:01 and HLA-DRB1*11:04 (ReF.
173
). The association of some HLA class II alleles with particular phenotypes in JIA provides support for the existence of particular clinical subtypes of JIA 33 . In addition, the overlap in HLA associations of oligoarticular JIA and RF-negative polyarticular JIA supports many analyses that have combined these two subgroups, which share early onset, female predominance and a high prevalence of antinuclear autoantibodies 206 . In 2017, HLA alleles were found to be shared between JIA subtypes and clinically similar types of adult inflammatory arthritis 33 . Notably, the HLA associations were stronger in the paediatric subtypes than in their adult counterparts, consistent with a greater degree of heritability. Genetically and immunologically similar diseases in adults and children ultimately might be reclassified as the same disease 207 . HLA alleles will be instrumental in such classifications.
Therapy
No hypothesis linking particular HLA alleles to autoimmune or inflammatory mechanisms has been proved conclusively. However, in SE-positive RA and HLA-B*27-positive AS, therapeutic strategies based on
Polygenic risk scores
Composite scores based on weighted contributions of a large number of allelic variants across the genome to provide greater stratification of risk, especially at the tail ends of the risk distribution.
www.nature.com/nrrheum mechanistic models might ultimately provide strong support for specific hypotheses (Figs 3,4 ; Supplementary  Fig. 2 ). For example, the model invoking SE-containing allele-specific presentation of post-translationally modified peptides can be tested by developing inhibitors of PAD4 (also known as PADI4) 208 . Alternatively, a critical contribution of T cell responses to citrullinated peptides in RA pathogenesis would be supported if RA disease activity is curbed by therapeutic vaccination or a T cell therapy focused on these neoantigens. Encouraging preliminary findings have been reported for immunotherapy with tolerogenic dendritic cells presenting citrullinated peptides in patients with RA 209 . In the HLA-B27 example, targeting T H 17 cellpromoting cytokines or IL-17 has proven therapeutic efficacy in AS 210, 211 , regardless of how HLA-B27 boosts T H 17 cell immunity, whereas targeting IL-23, specifically induced via the HLA-B27 misfolding-UPR pathway in the ER (Fig. 4) , has been ineffective 212 . If blocking KIR3DL2 or open conformations of HLA-B27 were efficacious in patients 213, 214 , such a finding would strongly support a pathogenic function for this interaction. Moreover, although the exact function of ERAP1 in AS is unclear, the fact that ERAP1 variants with reduced activity are protective suggests that enzyme inhibitors could be beneficial 215, 216 . Indeed, preliminary observations indicate that ERAP1 inhibitors limit the production of IL-17 by T H 17 cells from patients with AS ex vivo 130 . Furthermore, the shared HLA associations between adults and children in RF-positive arthritis or in SpA provide a rationale for testing treatments in children that have efficacy in adults. The use of drugs targeting the IL-17 axis, currently in use in adults 210, 211 , will probably become part of the armamentarium for HLA-B27-associated SpA in children 217 . Any therapeutic benefit from such an approach would support the notion of shared disease mechanisms in children and adults.
Prevention
Studies have begun to elucidate how genetic and environmental factors combine to affect disease risk. Smoking [59] [60] [61] and gingivitis 62, 63 are environmental risk factors for RA but only in individuals who carry SE-containing HLA-DRB1 alleles. In principle, this knowledge enables the identification of at-risk individuals so that preventive approaches, such as smoking cessation and oral hygiene, can be personalized. Such genetically targeted behaviour modification could become an increasingly viable strategy as the cost of genotyping declines. Polygenic risk prediction models that incorporate environmental risk factors are being evaluated as an approach to tailor disease prevention strategies 218 . The prospect of reducing the possibility of chronic rheumatic disease might motivate individuals who are genetically at risk of disease to adhere to preventive measures.
Conclusions
Rheumatology has been at the forefront of understanding the genetic basis of complex autoimmune conditions. Accumulating data support the idea that HLA molecules contribute to disease through a number of mechanisms, including the presentation of pathogenic neoantigens in RA and the production of pathogenic abnormal cell surface HLA-B27 conformations in AS. The therapeutic promise of such mechanistic insights remains to be fully realized. Meanwhile, genetic data are increasingly becoming available to rheumatologists, patients and individuals at risk. Such information might aid diagnosis, disease stratification and personalized treatment strategies.
Published online 15 May 2019
